Piotr Stepniak is a Director of Business Development at ExploRNA Therapeutics, a company bringing innovations to the mRNA modifications. Piotr is responsible for the commercialization of ExploRNA’s technology, therapeutics platform, and therapies. ExploRNA’s novel 5’ mRNA capping technology increases translation efficiency by even two orders of magnitude when compared to the industry standard cap. In his previous role, in a company focused on AI for Precision Medicine, Piotr lead the immunology group that created artificial intelligence-powered technology for designing novel immunotherapies. Prior to that, for the same company, he built a service business based on bioinformatics and data science for the US and EU markets. Piotr set up effective collaborations with partners from big pharma, biotech companies, start-ups, and academic institutions. He has a master’s degree in biotechnology from the Adam Mickiewicz University in Poznan, Poland, and is a co-author of SARS-CoV2 vaccine blueprints for targeting cellular response activation.
2:15 PM - 3:15 PM (PDT)
Monday, June 13
With the delivery of mRNA-based COVID-19 vaccines, mRNA earned its rightful place among the leading…